Finally, we tested the ability of HER2DX ERBB2 mRNA expression to predict CelTIL response in an independent dataset of 20 patients with early-stage HR+/HER2− breast cancer treated in Part B of the trial. Here, ERBB2 is linked to breast carcinoma.